Open AccessTreatment of Dementia With Bosutinib
Author(s) -
Kennedy Mahdavi,
Sheldon E. Jordan,
Hannah R Barrows,
Maša Pravdic,
Barshen Habelhah,
Natalie E. Evans,
Robin B. Blades,
Jessica Iovine,
Sergio Becerra,
Rachel A. Steiner,
Marisa Chang,
Santosh Kesari,
Alexander Bystritsky,
Ed O'Connor,
Hyman Gross,
F. Scott Pereles,
Mike Whitney,
Taylor Kuhn
Publication year - 2021
Publication title -
neurology. clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.674
H-Index - 29
eISSN - 2163-0933
pISSN - 2163-0402
DOI - 10.1212/cpj.0000000000000918
Subject(s) - bosutinib , dementia , hazard ratio , medicine , clinical dementia rating , tolerability , population , cognitive decline , confidence interval , psychiatry , adverse effect , tyrosine kinase , disease , receptor , environmental health , nilotinib
The pursuit of an effective therapeutic intervention for dementia has inspired interest in the class of medications known as tyrosine kinase inhibitors such as bosutinib.